| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Anthracycline-induced cardiotoxicity.
|
Ann Intern Med
|
1996
|
4.31
|
|
2
|
Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries.
|
Circulation
|
1996
|
3.82
|
|
3
|
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators.
|
Circulation
|
2000
|
3.61
|
|
4
|
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study.
|
Lancet
|
2001
|
2.23
|
|
5
|
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker.
|
Eur Heart J
|
2002
|
2.06
|
|
6
|
Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.
|
Circulation
|
2000
|
1.79
|
|
7
|
Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials.
|
Circulation
|
2001
|
1.70
|
|
8
|
Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.
|
Lancet
|
1999
|
1.68
|
|
9
|
Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial.
|
J Am Coll Cardiol
|
2000
|
1.63
|
|
10
|
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT.
|
Eur Heart J
|
2000
|
1.62
|
|
11
|
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes.
|
Eur Heart J
|
2004
|
1.59
|
|
12
|
Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.
|
Circulation
|
1999
|
1.59
|
|
13
|
Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.
|
Circulation
|
2001
|
1.54
|
|
14
|
Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial.
|
Circulation
|
2001
|
1.50
|
|
15
|
Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience.
|
Circulation
|
1999
|
1.49
|
|
16
|
Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators.
|
Circulation
|
2000
|
1.48
|
|
17
|
Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial.
|
Eur Heart J
|
2003
|
1.42
|
|
18
|
First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.
|
J Thromb Haemost
|
2005
|
1.42
|
|
19
|
Abciximab and atherosclerotic heart disease: use in percutaneous coronary intervention, acute coronary syndromes and acute myocardial infarction.
|
Int J Clin Pract
|
2003
|
1.40
|
|
20
|
Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease.
|
Am J Med
|
2000
|
1.39
|
|
21
|
Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes.
|
J Thromb Haemost
|
2004
|
1.39
|
|
22
|
Cell adhesion molecules in coronary artery disease.
|
J Am Coll Cardiol
|
1994
|
1.35
|
|
23
|
Abciximab reduces mortality in diabetics following percutaneous coronary intervention.
|
J Am Coll Cardiol
|
2000
|
1.33
|
|
24
|
Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty.
|
Circulation
|
1996
|
1.23
|
|
25
|
Is all unstable angina the same? insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). The CAVEAT-Investigators.
|
Am Heart J
|
1999
|
1.20
|
|
26
|
Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus.
|
Circulation
|
2001
|
1.12
|
|
27
|
Rapid platelet-function assay: an automated and quantitative cartridge-based method.
|
Circulation
|
1999
|
1.12
|
|
28
|
Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II.
|
J Am Coll Cardiol
|
1999
|
1.11
|
|
29
|
Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy.
|
Am J Cardiol
|
1999
|
1.10
|
|
30
|
The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends.
|
Am J Cardiol
|
2000
|
1.07
|
|
31
|
Abciximab readministration: results of the ReoPro Readministration Registry.
|
Circulation
|
2001
|
1.01
|
|
32
|
Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention.
|
JAMA
|
2001
|
1.01
|
|
33
|
Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.
|
Am J Cardiol
|
1995
|
1.01
|
|
34
|
Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.
|
Am Heart J
|
2000
|
0.97
|
|
35
|
Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators.
|
Circulation
|
2000
|
0.94
|
|
36
|
Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
|
Circulation
|
1999
|
0.94
|
|
37
|
Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials.
|
Heart
|
2003
|
0.94
|
|
38
|
Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.
|
J Am Coll Cardiol
|
2000
|
0.93
|
|
39
|
Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes.
|
Circulation
|
2000
|
0.92
|
|
40
|
Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.
|
Circulation
|
1998
|
0.91
|
|
41
|
Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model.
|
Circulation
|
1995
|
0.91
|
|
42
|
Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
|
Circulation
|
2001
|
0.88
|
|
43
|
Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions.
|
Circulation
|
2000
|
0.87
|
|
44
|
Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk.
|
Heart
|
2005
|
0.86
|
|
45
|
The PRESTO (Prevention of restenosis with tranilast and its outcomes) protocol: a double-blind, placebo-controlled trial.
|
Am Heart J
|
2000
|
0.86
|
|
46
|
Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT.
|
Circulation
|
2001
|
0.84
|
|
47
|
beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme rise.
|
Circulation
|
2001
|
0.83
|
|
48
|
Antithrombotic therapy in patients undergoing percutaneous coronary intervention.
|
Chest
|
2001
|
0.83
|
|
49
|
Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study).
|
Am J Cardiol
|
2001
|
0.83
|
|
50
|
The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions.
|
J Am Coll Cardiol
|
1998
|
0.82
|
|
51
|
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.
|
Circulation
|
1996
|
0.82
|
|
52
|
Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model.
|
J Am Coll Cardiol
|
2001
|
0.82
|
|
53
|
Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
|
J Am Coll Cardiol
|
1998
|
0.81
|
|
54
|
Restenosis--an open file.
|
Clin Cardiol
|
1996
|
0.80
|
|
55
|
Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators.
|
Circulation
|
1998
|
0.80
|
|
56
|
Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade.
|
J Am Coll Cardiol
|
1998
|
0.80
|
|
57
|
Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
|
Am J Cardiol
|
2000
|
0.80
|
|
58
|
Randomized evaluation of coronary angioplasty for early TIMI 2 flow after thrombolytic therapy for the treatment of acute myocardial infarction: a new look at an old study. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group.
|
Coron Artery Dis
|
1994
|
0.80
|
|
59
|
Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT).
|
J Am Coll Cardiol
|
1995
|
0.79
|
|
60
|
Differences in cardioprotective efficacy of adrenergic receptor antagonists and Ca2+ channel antagonists in an animal model of dilated cardiomyopathy. Effects on gross morphology, global cardiac function, and twitch force.
|
Circ Res
|
1993
|
0.79
|
|
61
|
Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
|
Am J Cardiol
|
1998
|
0.78
|
|
62
|
Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
|
Am J Cardiol
|
2001
|
0.78
|
|
63
|
Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
|
Cleve Clin J Med
|
2000
|
0.77
|
|
64
|
The benefit of abciximab in percutaneous coronary revascularization is not device-specific.
|
Am J Cardiol
|
2000
|
0.76
|
|
65
|
Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.
|
J Thromb Haemost
|
2004
|
0.76
|
|
66
|
Antithrombotic therapy with intracoronary stenting.
|
Heart
|
1997
|
0.76
|
|
67
|
Trickle down thrombolysis.
|
J Am Coll Cardiol
|
1993
|
0.75
|
|
68
|
Stent scrutiny.
|
JAMA
|
2000
|
0.75
|
|
69
|
Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention.
|
Circulation
|
1999
|
0.75
|
|
70
|
Abciximab (ReoPro) removal during cardiopulmonary bypass with a hemoconcentrator.
|
J Thorac Cardiovasc Surg
|
2000
|
0.75
|
|
71
|
Does stenting prevent diabetic arterial shrinkage after percutaneous coronary revascularization?
|
Circulation
|
1997
|
0.75
|
|
72
|
An overview of the results of the EPIC trial.
|
Eur Heart J
|
1995
|
0.75
|
|
73
|
Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience.
|
Am Heart J
|
1999
|
0.75
|
|
74
|
Chest pain--a strong predictor of adverse cardiac events following precutaneous intervention (from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial [EPISENT])].
|
Am J Cardiol
|
1999
|
0.75
|
|
75
|
Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor.
|
Eur Heart J
|
1995
|
0.75
|
|
76
|
Comparing physician-specific two-year patient outcomes after coronary angiography: methodologic issues and results.
|
J Am Coll Cardiol
|
1999
|
0.75
|
|
77
|
Clinical experience with abciximab during coronary revascularisation: an overview.
|
BioDrugs
|
1998
|
0.75
|
|
78
|
Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators.
|
Am Heart J
|
1999
|
0.75
|
|
79
|
Characterisation of the unsteady transport of labelled species in permeable capillaries: role of convective dispersion.
|
Phys Med Biol
|
1983
|
0.75
|
|
80
|
Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators.
|
J Am Coll Cardiol
|
2001
|
0.75
|
|
81
|
Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial.
|
Eur Heart J
|
2002
|
0.75
|
|
82
|
Experimental determination and mathematical model of the transient incorporation of cholesterol in the arterial wall.
|
Bull Math Biol
|
1990
|
0.75
|
|
83
|
Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
|
Eur Heart J
|
2000
|
0.75
|
|
84
|
Prospective case-control comparison of percutaneous transluminal coronary revascularization in patients with multivessel disease treated in 1986-1987 versus 1991: improved in-hospital and 12-month results. Multivessel Angioplasty Prognosis Study (MAPS) Group.
|
J Am Coll Cardiol
|
1995
|
0.75
|
|
85
|
Influence of local delivery of the protein tyrosine kinase receptor inhibitor tyrphostin-47 on smooth-muscle cell proliferation in a rat carotid balloon-injury model.
|
Am Heart J
|
1997
|
0.75
|
|
86
|
Role of longitudinal diffusion in the extravascular pulmonary space on parameter estimates derived from data of multiple indicator dilution.
|
Phys Med Biol
|
1982
|
0.75
|
|
87
|
Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention.
|
Am J Cardiol
|
1998
|
0.75
|
|
88
|
Platelet glycoprotein IIb/IIIa inhibitors combined with fibrinolytic agents to treat acute myocardial infarction.
|
J Thromb Thrombolysis
|
2001
|
0.75
|
|
89
|
Anti-inflammatory stent coatings: dexamethasone and related compounds.
|
Semin Interv Cardiol
|
1999
|
0.75
|
|
90
|
Quantitative evaluation of local drug delivery using the InfusaSleeve catheter.
|
Cathet Cardiovasc Diagn
|
1997
|
0.75
|
|
91
|
Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings.
|
Am Heart J
|
1998
|
0.75
|